ArticleJapanese journal of ophthalmology2026
Clinical characteristics and prognostic factors associated with recurrence in periocular basal cell carcinoma in a Taiwanese population.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBasal cell carcinoma (BCC) is the most common malignancy of the eyelid, with a significant risk of local recurrence despite its low metastatic potential. Understanding prognostic factors for recurrence is essential for optimizing treatment and improving patient outcomes. This study aimed to analyze the clinical characteristics and prognostic factors associated with recurrence in periocular BCC in a Taiwanese population. STUDY
designThis was a retrospective, single-center cohort study conducted at a tertiary medical center in Taiwan.
methodsWe reviewed 46 patients diagnosed with periocular BCC at National Taiwan University Hospital between 2000 and 2023. Data on demographics, tumor characteristics, surgical margins, and recurrence outcomes (both clinical and pathological) were collected. Recurrence-free survival was assessed using Kaplan-Meier analysis, and statistical analyses, including chi-square tests, Fisher's exact tests, and multivariate logistic regression, were performed to identify significant prognostic factors.
resultsThe mean age at diagnosis was 72.3 years, with a slight female predominance (54.4%). Tumors predominantly affected the lower eyelid (84.8%). The study identified a clinical recurrence rate of 30.4% with a 10-year recurrence-free survival (RFS) of 67.4%. Upon strict histological confirmation, the pathological recurrence rate was 23.9%, corresponding to an RFS of 73.7%. Multivariate analysis identified two robust independent predictors across both definitions. Compromised surgical margins were strongly associated with recurrence (Clinical: OR = 5.70, p < 0.001; Pathological: OR = 15.56, p < 0.05). Similarly, delayed surgical intervention (>12 months) significantly increased recurrence risk (Clinical: OR = 5.21, p = 0.001; Pathological: OR = 14.21, p < 0.05). Tumor size and thickness were correlated with recurrence in univariate analysis but did not reach statistical significance in the multivariate models.
conclusionCompromised surgical margins and delayed treatment are robust, major risk factors for recurrence in periocular BCC, regardless of whether a clinical or pathological definition is applied. While the clinical recurrence rate highlights the burden of re-operation, the pathological recurrence rate underscores the biological aggressiveness in neglected cases. Notably, achieving free margins resulted in excellent long-term control. These findings emphasize the critical need for early diagnosis and complete excision to improve patient outcomes.
Indexed as
Identifiers
42593602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.